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Identiﬁcation of a cancer stem cell-speciﬁc function for the
histone deacetylases, HDAC1 and HDAC7, in breast and
ovarian cancer
AE Witt1, C-W Lee2, TI Lee3, DJ Azzam4, B Wang1, C Caslini1, F Petrocca5, J Grosso1, M Jones1, EB Cohick2,3, AB Gropper3, C Wahlestedt4,
AL Richardson2, R Shiekhattar6, RA Young3 and TA Ince1
Tumours are comprised of a highly heterogeneous population of cells, of which only a small subset of stem-like cells possess the
ability to regenerate tumours in vivo. These cancer stem cells (CSCs) represent a signiﬁcant clinical challenge as they are resistant to
conventional cancer therapies and play essential roles in metastasis and tumour relapse. Despite this realization and great interest
in CSCs, it has been difﬁcult to develop CSC-targeted treatments due to our limited understanding of CSC biology. Here, we present
evidence that speciﬁc histone deacetylases (HDACs) play essential roles in the CSC phenotype. Utilizing a novel CSC model, we
discovered that the HDACs, HDAC1 and HDAC7, are speciﬁcally over-expressed in CSCs when compared to non-stem-tumour-cells
(nsTCs). Furthermore, we determine that HDAC1 and HDAC7 are necessary to maintain CSCs, and that over-expression of HDAC7 is
sufﬁcient to augment the CSC phenotype. We also demonstrate that clinically available HDAC inhibitors (HDACi) targeting HDAC1
and HDAC7 can be used to preferentially target CSCs. These results provide actionable insights that can be rapidly translated into
CSC-speciﬁc therapies.
Oncogene (2017) 36, 1707–1720; doi:10.1038/onc.2016.337; published online 3 October 2016
INTRODUCTION
The cancer stem cell (CSC) model posits that each tumour is
composed of a hierarchy of cells, of which only a small subset are
CSCs that possess the ability to regenerate tumours in vivo.1 The
remaining tumour bulk is primarily comprised of non-stem-
tumour-cells (nsTCs) that descend from CSCs but are themselves
incapable of initiating or propagating tumours.
Multiple signalling pathways involved in the regulation of CSCs
have been identiﬁed.1 However, the regulation of CSCs is unlike
the reversible short-term changes in cellular phenotype induced
by various extracellular factors, or the permanent changes
induced by mutations. The hierarchical differentiation of CSCs to
nsTCs is long-lasting over many cell generations but it is also
reversible, that is more akin to tissue differentiation, which
suggests that epigenomic factors such as histone modiﬁcations
may also be involved in the regulation of the CSC phenotype.2
HDACs are chromatin-modifying enzymes that are involved in
regulation of many aspects of cell biology including tissue
differentiation, autophagy, apoptosis, migration, mitosis and
angiogenesis.3 There are 11 different HDAC genes with distinct
tissue-speciﬁc expression. The HDAC proteins are grouped by their
homology to their orthologues in yeast; class I (HDAC 1-3, 8); class
II a (HDAC 4, 5, 7, 9), class II b (6 and 10), and class V (HDAC 11).3
While the total pan-HDAC activity, including all family members,
have been implicated in differentiation, pluripotent and
embryonic stem cell regulation,4–10 the role of speciﬁc HDACs in
the regulation of CSCs has not been fully explored.
The exploration of the epigenetic factors that may be involved
in the regulation of CSCs has been hampered by experimental and
technical challenges, which we partly address in this study. The
CSCs can be isolated with ﬂuorescence-activated cell sorting
(FACS), using antibodies that recognize putative CSC cell surface
markers.1,11–22 However, the rare nature of CSCs in solid tumours,
coupled with the methodological challenges of isolating and
expanding them in vitro, has impeded the identiﬁcation of the
precise epigenetic regulators responsible for maintaining CSC
phenotype.
It is worth pointing out that FACS enrichment of CSCs from
primary tumours is not an innocuous process, because it exposes
the tumour cells to many changes in temperature, CO2 and pH
levels. Since isolation of CSCs by FACS requires single cell
suspensions as starting material, the solid tumour fragments are
ﬁrst digested with proteases (such as collagenase and trypsin) at
37 °C for several hours depending on the tissue type (1–8 h). Next,
the resulting single cell suspension is incubated with CSC-speciﬁc
antibodies at 4 °C for 1–2 h, followed by FACS enrichment at 20 °C
for another 1–2 h. At the end of this process, in our experience
101–3 fold enrichment of CSCs relative to nsTCs can be achieved
by combining two to three CSC surface markers. However, if one is
working with a cell line or tumour type with a low 10− 5 to 6 CSC
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frequency, this would represent at best only one in a hundred cells
in the enriched population are indeed CSCs. Therefore, one can
isolate relatively CSC-enriched populations with FACS; however,
these are not CSC-pure populations by any means. Lastly, even
when CSC populations are successfully isolated with FACS, their
phenotypic instability limits their utility, because CSCs rapidly
differentiate into nsTC in standard culture.14
In summary, while FACS enrichment is used as a benchmark
method to study CSCs, the lack of absolute purity, rapid dilution
and potential alterations in CSC phenotype are some of the
drawbacks of this approach. In this manuscript we describe a
model system that addresses some of these methodological
challenges, leading to identiﬁcation of several HDACs involved in
the regulation of CSC phenotype in several model systems.
RESULTS
BPLER cell lines as a model of CSCs
The technical challenges associated with isolation and study of
CSCs can be partly circumvented by utilizing a set of gene-
tically engineered cell lines that functionally ‘phenocopy’ CSC
behaviours. Previously we derived three independent pairs of
genetically matched breast cancer cell lines, BPLER2–4 and
HMLER.2–4,23 The BPLER lines were derived from normal
human breast precursor epithelial cells that have a mixed
luminal-myoepithelial phenotype and maintain telomerase activ-
ity in vitro.23,24 In contrast, HMLERs are derived from normal
human mammary epithelial cells that exhibit a more differentiated
myoepithelial phenotype and do not have telomerase activity.23,24
Both high levels of hTERT activity and lack of lineage commitment
have been associated with stem cells in normal tissues. Consistent
with the difference in their cell-of-origin, we now demonstrate
that BPLER cells recapitulate the mRNA expression proﬁle and the
biological properties of CSCs. In contrast, HMLER cells as a whole
resemble nsTCs (Supplementary Figures 1–7).
Importantly, the frequency of CSCs in unsorted bulk BPLER
cultures is equivalent to the CSC population obtained after FACS
enrichment of standard cell lines and is stably maintained in
routine 2D culture. Hence, while as few as ﬁve unsorted BPLER cells
are capable of forming tumours in nude mice, the genetically
matched HMLERs require injection of 103–5 cells to form tumours
in vivo (Figure 1a). The CSC-like BPLERs also form signiﬁcantly
higher number of tumour spheres compared to matched HMLER
lines (Figure 1b), which is a measure of CSC frequency in vitro.25–29
In addition, the BPLER CSC phenotype is stable, maintaining
high endogenous levels of the CSC-associated markers
CD166,1,11–16 CD326 (EpCAM, ESA),18–20 CD44v22 and BMI-12
throughout extended periods of culture (Figure 1c), and the CSC
attributes of BPLER can be even further enhanced by FACS
enrichment using individual CSC markers, in particular, CD44 and
Figure 1. BPLER and HMLER cells differ in their in vivo and in vitro tumor initiating cell (TIC) frequency, and in CSC surface marker expression.
(a) In serial dilution xenograft assays BPLER lines display 2–4 orders-of-magnitude (102–104) greater in vivo TIC frequency than paired HMLER
cell lines. BPLER2/HMLER2, BPLER3/HMLER3, BPLER4/HMLER4 isogenic cell lines were derived from normal human breast primary cells isolated
from three different donors as previously described23 (See Supplementary Figure 2a for further details). (b) BPLER lines (blue bars)
demonstrate greater capacity for sphere formation than HMLER cells (red bars) in 3D sphere formation assays used as an in vitro measurement
of CSC self-renewal. Data presented as a mean +/− s.d. of sphere counts from triplicate wells (Po0.05). Results are representative of at least
three independent experiments. (c) BPLER lines express higher levels of the CSC markers CD326 (EpCAM/ESA), CD166 (ALCAM), and BMI-1*
than HMLER. Additionally, BPLER lines express the CSC-speciﬁc CD44 isoform (CD44v-250 kDa), while HMLER express the standard CD44
isoform (CD44s-80 kDa). Western blot of whole-cell lysates. β-Actin represents loading control. *BMI-1-matched β-actin in Supplementary Fig
ure 3f. (d) FACS-enriched BPLER CSCs, sorted for high expression of individual CSC markers (CD44, CD166, CD326), or a combination of all
three markers, demonstrate enhanced mammosphere formation when compared to BPLER with low CSC-marker expression (black bars, CSC
marker high; white bars, CSC marker low). Data presented as a mean +/− s.d. of sphere counts performed in triplicate (Po0.05). Results are
representative of at least three independent experiments.
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CD166 (Figure 1d). The unique stability of the CSC phenotype in
the BPLER model enabled us to carry out the CSC-speciﬁc
experiments described below, which would not have been
possible with conventional cell lines.
Lastly, we found that the BPLER cells co-cluster with the triple-
negative breast cancer (TNBC) cell lines (Supplementary Figure 4),
TNBC patient tumours (Supplementary Figures 5 and 6), express a
CSC-like mRNA expression signature identiﬁed in other cell lines
(Supplementary Table 1), and recapitulate the accurate human
breast adenocarcinoma morphology in xenograft tumours
(Supplementary Figures 7 and 8). These results cumulatively
indicate that the BPLER model at least partially phenocopies
naturally occurring CSCs.
Discovery of CSC over-expression of HDAC1 and HDAC7
in BPLER CSCs
We hypothesized that speciﬁc members of the HDAC family,
chromatin-modifying enzymes involved in epigenetic regulation
of differentiation, might be involved in the regulation of the CSC
phenotype in BPLERs. Since the CSC-like BPLER and nsTC-like
HMLER cell line pairs are derived from the same patient and
transformed with identical oncogenes, they are ostensibly
isogenic, which makes them a good model system to survey
epigenetic differences between CSC and nsTC. In order to
initially examine these potential epigenetic differences, the paired
BPLER/HMLER lines were treated with Trichostatin A (TSA), a
pan-HDACi that inhibits all the HDAC family members. These dose-
response studies reveal that BPLER proliferation is signiﬁcantly
more sensitive to TSA inhibition as compared to matched HMLERs
in 2D culture (Figure 2a).
Next, we tested the effect of short-term (24 h) TSA treatment on
subsequent 2D proliferation in routine culture vs 3D sphere
formation, a surrogate assay for measuring CSC frequencies.
Interestingly, we found that TSA pretreatment preferentially
inhibits BPLER sphere formation (3D growth). In contrast, standard
chemotherapeutics preferentially inhibit HMLERs and 2D prolif-
eration (Figure 2b, Supplementary Figures 9a and b). Furthermore,
these conventional chemotherapeutics (Taxol, 5-ﬂuorouracil and
Doxorubicin) preferentially induce apoptosis in HMLERs, but not
BPLERs (Supplementary Figure 9c), consistent with the chemother-
apeutic resistance typically associated with CSCs. Finally, TSA
pretreatment preferentially inhibits 3D growth of standard breast
cancer cell lines as compared to 2D proliferation (Supplementary
Figure 9d). These ﬁndings demonstrate that short-term treatment
with a pan-HDACi has lasting effects on sphere-initiating capacity
in multiple models, and this effect is not simply due to a non-
speciﬁc inhibition of cell proliferation.
These results prompted us to evaluate whether speciﬁc HDAC
family members are expressed at higher levels in CSC-like BPLERs
compared to nsTC-like HMLERs. We found that only two of the 11
HDAC family members, HDAC1 and HDAC7, were consistently
expressed at signiﬁcantly higher levels in BPLER lines at the
protein level (Figure 2c). Interestingly, there is no consistent
difference at the mRNA level between BPLER and HMLER lines for
any of the HDACs 1–11 (Figure 2d), suggesting that these
differences are maintained at the protein level in CSCs. The
regulation of HDACs at the protein level may be one reason why
the association between CSCs and HDAC1/7 has not been
identiﬁed in previous mRNA proﬁling experiments. Furthermore,
we found that TSA treatment of BPLER lines downregulates
HDAC1 and HDAC7 protein expression, as well as CD44 and
CD166, suggesting that HDAC-dependent mechanisms may
regulate these CSC markers (Figure 2e). Consistent with this,
immunoﬂuorescent (IF) staining of unsorted BPLER cells revealed
that CD44high/CD166high-CSC subpopulations express higher levels
of HDAC7 (and HDAC1, data not shown) compared to CD44low or
CD166low cells (Figure 2f).
Veriﬁcation of HDAC1 and HDAC7 over-expression in primary
tumour and cell line CSCs
In order to verify these results in other models, we used FACS to
isolate CSCs. Consistent with previous reports, we observed
that CD44high/CD166high populations have greater sphere-
forming capacity compared to (CD44low/CD166low) counterparts
(Figure 3a)(1,11–14). CD44high/CD166high CSCs from multiple breast
(SUM159, MDA-MB-231, MCF7), ovarian (SKOV3, OV90) and colon
(HT29) tumour cell lines. These FACS-enriched CSC subpopulations
demonstrate increased HDAC enzymatic activity (Figure 3b), and
in agreement with the BPLER/HMLER system, consistently
expressed signiﬁcantly higher HDAC1 and HDAC7 levels com-
pared to paired nsTC populations (Figure 3c, Supplementary
Figure 10a). Consistent with these ﬁndings, IF staining conﬁrmed
that CD44high/CD166high cells express higher levels of HDAC7
compared to CD44low/CD166low cells (Figure 3d, Supplementary
Figures 10b and c). While several other HDAC family members
have variable expression patterns in sorted CSCs, among these
HDAC1 and HDAC7 are most consistently associated with CSCs in
all cell lines examined.
In addition to CD44 and CD166, we veriﬁed the association
between HDAC7 overexpression and CSC phenotype using six
additional CSC markers (ALDH1a1, ALDH1a3, CD29, CD44v, CD49f
and CD326) in a panel of seven additional breast and ovarian
cancer lines. These experiments identiﬁed a broad correlation
between high HDAC7 protein expression with a variety of well-
established CSC markers (Figure 3e, Supplementary Figure 10d).
These results were also conﬁrmed in tumour cells freshly isolated
from seven primary human ovarian and breast cancers,30 and in
formalin-ﬁxed parafﬁn-embedded sections of primary human
breast cancer tissues (Supplementary Figure 11). In sum, we
observed a correlation between eight CSC markers and high
HDAC7 protein expression in seven cell lines and seven primary
tumours using IF staining. These results establish an association
between high HDAC1/7 protein and CSCs in multiple cell line
models and primary tumour cells.
Re-identiﬁcation of HDAC inhibitors through a BPLER siRNA
lethality screen
Reassuringly, HDAC sensitivity of the BPLER lines was conﬁrmed in
an independent genome-wide high-throughput unbiased siRNA
lethality screen.31 A genome-wide siRNA screen was used to
identify 154 genes that are speciﬁcally lethal when inhibited in
BPLER cells but not in HMLER cells.31 This signature correlates with
poor survival and early onset of metastasis in breast cancer
patients independent of tumour subtype.31 We interrogated the
mRNA expression of these 154 genes in the Broad Institute
connectivity map (CMAP), which contains mRNA expression data
from cancer cell lines exposed to 1309 compounds in over 7000
experiments.31 This analysis identiﬁed 37 compounds that
preferentially reduced the expression of 154 BPLER-lethality genes
in other cell lines (Supplementary Table 2). Interestingly, the
HDACi, TSA, was the top candidate that emerged out of this in
silico screen, and Vorinostat (SAHA) was the fourth most signiﬁcant
(Figure 4a). Next, we evaluated the dose-response of BPLER vs
HMLER cells to the top 10 compounds, and found that only the
pan-HDACis, TSA and SAHA have differential efﬁcacy towards
BPLER (Figure 4b). Interestingly, the other eight in silico candidate
compounds did not exhibit any differential effects on BPLER vs
HMLER cells (Figure 4b, Supplementary Figure 12). Hence, we
found the same differential HDAC sensitivity between BPLER and
HMLER cells, both by a hypothesis-driven candidate-based
approach and a high-throughput unbiased approach. Remarkably,
the two HDAC inhibitors were the only two candidate hits that
were conﬁrmed from the high-throughput screen.
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Re-identiﬁcation of HDAC inhibitors in a small molecule CSC
lethality screen
In order to conﬁrm the HDAC sensitivity of CSC-like BLERs in other
CSC models, we used FACs-isolated CD44high/CD24low+ MDA-
MB-231 CSCs. This subpopulation of cells have been previously
shown to possess greater sphere-forming potential, increased
capacity for tumour-initiation and metastasis in xenograft models,
and higher expression of stem-like and metastatic mRNA
signatures compared to CD44high/CD24neg cells.17,32 Consistent
with the BPLER results, we found that the CD44high/CD24low+ CSCs
express signiﬁcantly higher HDAC1, HDAC7 and CD166 proteins
compared to their CD44high/CD24neg counterparts (Figure 4c). Also
Figure 2. CSC-Like BPLER cells are associated with high HDAC1 and HDAC7 expression and sensitivity to pan-HDAC inhibitors. (a) The
pan-HDAC inhibitor TSA preferentially inhibits BPLER proliferation (blue line), compared to HMLER (red line). The results are representative of
at least three independent experiments, presented as a percentage of vehicle treated control, the error bars represent standard deviation of
the mean (Po0.005). (b) Short-term (24 h) pretreatment with TSA (0.35 μM), preferentially inhibits BPLER sphere formation (3D) in drug-free
medium with no effect on 2D proliferation in either BPLER or HMLER. In contrast, pretreatment with Taxol (50 nM) and 5-Fluorouracil (1.0 μM),
preferentially inhibit 2D proliferation as compared to 3D sphere formation. The number of viable colonies from triplicate wells were
determined by 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-phenyl-2H-tetrazolium chloride (INT) staining. Results are representative of at least three
independent experiments presented as percentage of vehicle treated control (Po0.05). BPLER: 2D proliferation (white bars with blue outline)
vs 3D sphere formation (blue bars). HMLER: 2D proliferation (white bars with red outline) vs 3D sphere formation (red bars). The error bars
represent standard deviation of the mean. (c) BPLER cell lines express higher levels of HDAC1 and HDAC7 proteins compared to matched
HMLER lines. Western blot of whole-cell lysates. β-Actin represents loading control. (d) Heatmap of the mRNA expression proﬁle of HDAC1-11
does not reveal any consistent differences between BPLER and HMLER lines (red, increased expression; green, decreased expression).
(e) Treatment of BPLER cells for 48 h with TSA (0.35 μM) leads to downregulation of HDAC1, HDAC7, CD44 and CD166 protein expression in
BPLER cells. Western blot of whole-cell lysates. β-Actin represents loading control. (f) Double immunoﬂuorescence staining of BPLER cells
simultaneously with HDAC7 and CD44 antibodies demonstrate that HDAC7 and CD44 are co-expressed. DAPI (blue), HDAC7 (red) CD44
(green). Scale bar 25 μM.
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reminiscent of the BPLER results, this difference was only present
at the protein level, with no signiﬁcant difference in HDAC mRNA
level (Figure 4d).
Having conﬁrmed the association between CSCs and HDAC1/7
in this second cell line model, we used the CD44high/CD24low+
CSCs to screen a library of 60 epigenetic-targeting-compounds.
This analysis identiﬁed 12 compounds that preferentially inhibit
CD44high/CD24low+ MDA-MB-231 CSC population in cell viability
assays. Interestingly, 11 of the 12 positive hits turned out to be
HDACis, including TSA and Vorinostat (Figure 4e). Also, consistent
with BPLER/HMLER, GSK126, which speciﬁcally inhibited the less
tumorigenic, CD44high/CD24neg MDA-MB-231 population in this
assay also preferentially inhibits HMLERs (data not shown). In
conclusion, these results establish an association between high
HDAC1/7 protein, HDAC activity and CSCs in an independent cell
line model.
HDAC1 and HDAC7 are necessary to maintain the CSC phenotype
Given the high levels of HDAC1 and HDAC7 expression in CSC
subpopulations, we sought to determine whether these HDACs
were necessary to maintain the CSC phenotype. Using shRNA or
CMV-driven constructs, we knocked down or overexpressed each
HDAC in multiple breast and ovarian cell lines and examined the
effects on the CSC phenotype. Experimental lines were selected
based on endogenous HDAC1/7 expression levels (Supplementary
Figures 13 and 14).
Consistent with a role for HDACs in CSC regulation, HDAC1
depletion decreases CSC marker expression, and inhibits sphere
formation (3D) and 2D cell proliferation (2D) (Figures 5a and b).
These results are conﬁrmed with additional shRNA constructs in
multiple cell lines (Supplementary Figure 13). Furthermore,
HDAC1-shRNA expression results in signiﬁcant reduction in
xenograft tumour size and ~ 4-fold reduction in tumour-
initiating cell (TIC) frequency compared to control cells expressing
a scramble-shRNA construct (Figures 5c and d).
Short-term HDAC7 depletion also decreases CSC marker
expression, and inhibits 3D proliferation to a signiﬁcantly greater
extent than 2D in multiple cell lines, conﬁrmed with several shRNA
constructs (Figures 5e and f, Supplementary Figure 14). The speciﬁc
inhibition of sphere formation, with lesser effects on 2D cell growth,
suggests that reduction of sphere formation by CSCs with HDAC7
depletion is not simply due to a non-speciﬁc effect on regular cell
proliferation. We found that HDAC7 protein is upregulated
within several passages in HDAC7-shRNA cells with all three
HDAC7-shRNA constructs (Supplementary Figures 15a and b).
Figure 3. CSCs isolated from standard breast and ovarian cancer cell lines express higher protein levels of HDAC1 and HDAC7, and have
increased HDAC enzymatic activity. (a) The higher sphere forming capacity of CD44high/CD166high CSCs (black bars) compared to CD44low/
CD166low nsTC cells (white bars) is observed in multiple breast (SUM159, MDA-231, and MCF7) and ovarian (SKOV3 and OV90) cell lines. The
data are presented as the mean of sphere counts from triplicate wells, the error bars represent standard deviation of the mean (Po0.01). The
results are representative of at least three independent experiments. (b) The higher HDAC enzyme activity is observed CD44high/CD166high
CSCs (black bars) compared to CD44low/CD166low nsTCs (white bars) in multiple breast (SUM159, MDA-231, and MCF7) and ovarian (SKOV3
and OV90) and colon (HT29) cancer cell lines. Results are representative of at least three independent experiments. The error bars represent
standard deviation of the mean (Po0.01). (c) HDAC1 and HDAC7 protein expression is signiﬁcantly higher in CD44high/CD166high CSCs (+/+)
from multiple breast (BPLER, MDA-MB-231, MCF7, SUM159) and ovarian (SKOV3) cancer cell lines compared to nsTC (− /− , CD44low/CD166low).
Merged image of two Western blots run with whole-cell lysates, gel#1(BPLER, MDA-MB-231, MCF7, SUM159) and gel#2(SKOV3). β-Actin
represents loading control. (d) HDAC7high (red) and CD44high (green) co-expression in ovarian cancer cell line SKOV3, demonstrated with
double IF staining. Scale bar 25 μM. (e) Double IF staining identiﬁes co-expression of CSC-markers (CD44, CD326, CD166, ALDH1, CD29) with
HDAC7 in standard breast cell lines (MDA-MB-231, MCF7, SUM159), and primary human ovarian (OCI-P5x and OCI-E1p) and breast cancer cells
(BCI-1009 and BCI-1133). (Y) represents consistent positive correlation of HDAC7 and CSC marker expression in surveyed lines. (y) represents
positive, but inconsistent correlation. (N) represents lack of correlation. (n/a), not analyzed. (n/e) CSC marker not expressed in cell line. IF
staining was repeated a minimum of two times for each line. See Supplementary Figure 10 for additional markers and cell lines.
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Therefore, long-term in vivo tumorigenesis analysis with stable cell
lines expressing HDAC7-shRNA was not possible. The short-term
shRNA results were also conﬁrmed using transient siRNA
transfection (Supplementary Figures 15c and d).
HDAC7 is sufﬁcient to augment the CSC phenotype
These knockdown experiments indicate that HDAC1 and HDAC7
are necessary for the maintenance of the CSC phenotype. We next
examined whether HDAC1 or HDAC7 overexpression are also
sufﬁcient to augment the CSC phenotype. We found that HDAC7
overexpression upregulated CSC markers, increased sphere forma-
tion two- to sixfold, and signiﬁcantly enhanced sphere size, without
any effect on 2D proliferation, as compared to control cells
expressing the empty vector (Figures 6a–c, Supplementary
Figure 16). Furthermore, HDAC7 overexpression in MCF7 cells
upregulates 334 pro-metastatic or CSC-associated genes, alters gene
expression of CSC-associated metabolic pathways,33 and down-
regulates expression of established HDAC7 targets34 and micro-
RNAs associated with CSC phenotype (Supplementary Data 1,
Supplementary Tables 3–5). Finally, in vivo limiting dilution analysis
demonstrates that HDAC7 over-expression increases TIC frequency
approximately twofold (Figure 6d). These ﬁndings indicate that
HDAC7 is necessary and sufﬁcient for augmenting the CSC
phenotype in these breast cancer cell lines.
Transcriptional self-repression of HDAC1 has been previously
reported.35 Consistent with this, we were not able to overexpress
HDAC1 in multiple cell lines due to downregulation of endogen-
ous HDAC1 levels (Supplementary Figures 17a and b). Conse-
quently, while we did observe a small increase in 2D proliferation
(up to twofold) in some cell lines expressing the HDAC1-CMV
construct, there was no increase in sphere formation
(Supplementary Figure 17c).
Inhibition of HDACs with class-speciﬁc drugs inhibits CSC
phenotype
Motivated by the potential clinical implications of these ﬁndings
we explored the effect of isoform-speciﬁc HDACis on CSC
proliferation. While pan-HDACis (SAHA and TSA) have been used
Figure 4. Conﬁrmation of CSC sensitivity to pan-HDAC inhibitors in other model systems. (a) The black lines within the red and green regions
indicate different CMAP experiments that display signiﬁcant upregulation (red) or downregulation (green) of the 154 BPLER lethality genes
upon treatment with the indicated drugs. Black lines in the gray area indicate CMAP experiments with no signiﬁcant variation. (b) The percent
viability of BPLER and HMLER cells that were treated with TSA, Vorinostat, Loperamide and Triamterene at the indicated doses. A vehicle-
treated control was used to estimate relative percent cell viability for each treatment. BPLER (blue line), HMLER cells (red line). The error bars
represent standard deviation of the mean (Po0.005). (c) HDAC1, HDAC7 and CD166 proteins are expressed signiﬁcantly higher in the
CD44high/CD24low+ CSCs (CD24L) compared to CD44high/CD24Neg ns-TS (CD24N) MDA-MB-231 cells. Western blot of whole-cell lysates. β-Actin
represents loading control. (d) The mRNA expression heatmap of CD44high/CD24low+ CSCs (CD24L) compared to CD44high/CD24Neg nsTC
(CD24N) MDA-MB-231 cells, with high (red) and low (green) expression. The difference in expression for any HDAC family members between
the two populations was less than 1.1 fold. (e) The sensitivity of CD24-negative (CD24N) vs CD24-low (CD24L) MDA-MB-231 cells to 60
epigenetic compounds was measured. The upward sloping curve marked with blue stars indicate 12 of drugs that preferentially inhibit the
proliferation CD44high/CD24low+ MDA-MB-231 CSCs. including Trichostatin (a1), Apicidin (a6), Scriptaid (a8), Vorinistat (a12), M-344 (b8), Fluoro-
SAHA (b12), Oxamﬂatin (c10), BML-281 (d6), Rocilinostat (e5), CUDC-907 (e6), CUDC-101 (e7). Dimethyl sulfoxide controls are shown in the last
two rows. The red star identiﬁes one compound (GSK126) that selectively killed CD24neg cells.
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to target CSCs,36–39 these HDACis indiscriminately target all 11
HDAC family members, resulting in toxicity that limits their clinical
use.40 Consequently, we hypothesized that HDAC1/7-speciﬁc
HDACis might prove more selective in inhibiting CSCs compared
to pan-HDAC inhibitors. Although drugs that inhibit single HDAC
isoforms are not currently available, we were able to obtain class
selective HDACi.
Of particular interest, we discovered that MS275 (Entinostat)
and MGCD0103 (Mocetinostat), members of the benzamide class
of HDACi known to speciﬁcally inhibit HDAC1/2/3 enzyme
Figure 5. Knockdown of HDAC1 or HDAC7 alters the CSC phenotype in breast and ovarian cancer cell lines. (a) The knockdown of HDAC1 with
shRNA reduces HDAC1, CD44 and CD166 protein levels in breast (MDA-MB-468/MCF7) and ovarian (SKOV3) cancer cell lines compared to a
scramble shRNA control. Western blot of whole-cell lysates. β-Actin represents loading control. (b) HDAC1 knock-down with shRNA decreases
3D sphere formation (dark blue bars) more signiﬁcantly than 2D proliferation (light blue bars) as compared a scramble shRNA-expressing
control (white bars) in breast (MDA-MB-468, and MCF7) and ovarian (SKOV3) carcinoma cell lines. The data are presented as a percentage of
the scramble shRNA controls. The error bars represent standard deviation of the mean from three replicates (*Po0.05)(**Po0.005). The
results are representative of at least three independent experiments. Similar results were observed with additional HDAC1 shRNA constructs
and in additional cell lines (Supplementary Figures 5b–d). (c) HDAC1 knockdown decreases tumour size in SUM159 breast cancer xenografts
expressing two different stable HDAC1-shRNAs (shH1#1 and shH1#2) as compared to control scramble shRNA (shCntrl). Mean xenograft size
measured from mice injected with 10 000 cells and plotted over time weeks) (Po0.05). (d) HDAC1 knockdown decreases tumour frequency in
MDA-MB-231 xenografts expressing stable HDAC1-shRNA as compared to a scramble shRNA control line. TIC frequency calculated by limiting
dilution analysis using http://bioinf.wehi.edu.au/software/elda/. TIC frequency of control cells (1.05 × 10− 5), HDAC1 shRNA#1 (4.42 × 10− 5)
(Po0.005) and HDAC1 shRNA#2 (4.62 × 10− 5) (Po0.005). (e) The knockdown of HDAC7 with shRNA reduces HDAC7, CD44 and CD166 protein
levels compared to a scramble shRNA control in breast (MDA-MB-468, and MCF7) and ovarian (SKOV3) carcinoma cell line within 72 h western
blot of whole-cell lysates. β-Actin represents loading control. (f) HDAC7 knockdown with shRNA decreases 3D sphere formation (dark green
bars) more signiﬁcantly than 2D proliferation (light green bars) as compared to a scramble shRNA-expressing control (white bars) in breast
(MDA-MB-468, and MCF7) and ovarian (SKOV3) carcinoma cell lines. The results from one shRNA construct is shown, similar results were
observed with additional HDAC7 shRNA constructs and in additional cell lines (Supplementary Figure 5). The cells are counted after trypan
blue (2D) or INT staining (3D), and the results are presented as a percentage of the scramble shRNA control. The error bars represent standard
deviation of the mean from three replicates (*Po0.05) (**Po0.01). The results are representative of at least three independent experiments.
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activity,41,42 dramatically downregulated HDAC7 protein levels,
with limited effects on the protein levels of other HDAC family
members (Figure 7). Based on our knockdown experiments
implicating both HDAC1 and HDAC7 as necessary for the
maintenance of the CSC phenotype, we found that both drugs
preferentially target CSCs, as a 4-day treatment killed 485 % of
BPLER population (as compared to vehicle treated controls), while
having no effect on HMLER proliferation (Figure 7a). This
differential effect was apparent as early as 24 h post-treatment.
Furthermore, 24-h pretreatment of SUM159 with MS275 decreases
the number of CD44hi/CD166hi, CD44hi/CD133hi and CD44hi/
CD326hi cells as seen by FACS analysis (Supplementary Figure 18).
In order to rule out MS275 and MGCD0103 effects on HDAC2
and HDAC3, we treated BPLER with the HDAC2/3/8-selective
Apicidin and HDAC3/6/8-selective Droxinostat,43,44 and deter-
mined that neither drug downregulates HDAC7 protein levels
(Figure 7c). As anticipated from our results, neither drug
preferentially inhibits BPLER proliferation (Figure 7a). These results
indicate that the selective effects of benzamides on BPLER appear
to be due to the combined inhibition of HDAC1 and HDAC7, and
not related to HDAC3 or HDAC8.
While single isoform HDAC7-speciﬁc inhibitors are not yet
available, HDACi that enzymatically inhibit HDAC4/5/7/9 have
been developed (MC1568 and MC1575). Although these drugs
inhibit HDAC7 enzymatically, they do not alter HDAC7 protein
levels (Figure 7c). Interestingly, these drugs preferentially reduce
2D BPLER proliferation, with no effect on HMLER lines (Figure 7a),
but have no effect on sphere formation (Figure 7b and data not
shown), suggesting combined pharmacological inhibition of
HDAC1 and downregulation of HDAC7 protein is important for
CSC-speciﬁcity.
To conﬁrm these ﬁndings in other models we treated several
standard breast and ovarian cancer cell lines with the HDACi panel
using low-dose, short-term (24 h) pretreatments determined by
dose-response studies to have minimal effects on subsequent 2D
growth. Compellingly, these studies reiterate that, while pretreat-
ment with MS275 or MGCD0103 signiﬁcantly reduces or
eliminates sphere formation, pretreatment with MC1568 or
MC1575 has limited effects on sphere formation in most lines
(Figure 7c and data not shown). Similarly, pretreatment with
Droxinostat or Apicidin had minimal effects on sphere formation
(Figure 7c and data not shown). In addition to standard cell lines,
we repeated these experiments in a panel of primary human
ovarian cancer cell lines recently established by our lab,45 and
observed that MS275 pretreatment also inhibits sphere formation
in all primary lines tested (Figure 7d). Consistent with our results
with BPLER cells, these ﬁndings suggest that MS275 or MGCD0103
inhibition of sphere-formation is not due to a generic inhibition of
cell proliferation, and support the concept that these HDACis
speciﬁcally inhibit CSCs. Furthermore, we found that MS275
treatment of BPLER cells reduces HDAC7 chromatin binding at
stem cell associated transcription factor genes (Supplementary
Figure 6. Overexpression of HDAC7 alters the CSC phenotype in breast and ovarian cancer cell lines. (a) HDAC7 over-expression (H7) increases
CD44 and CD166 protein expression in MCF7 and SUM159, and CD44v(*) in SUM159 and HCC1937, compared to control cells expressing
empty vector (EV). Western blot of whole-cell lysates. β-Actin represents loading control. (b) HDAC7 overexpression increases 3D sphere
formation (dark green bars) with minimal effect on 2D proliferation (light green bars), as compared to an EV-expressing control (white bars), in
breast (MCF7/HCC1937) and ovarian (CaOV3) cell lines. 2D growth assays were counted after trypan blue staining to assess viable cells counts.
3D sphere assays were counted after INT staining. The data is presented as a percentage of the EV-expressing control. The error bars represent
standard deviation of the mean from triplicates (*Po0.05) (**Po0.01). The results are representative of at least three independent
experiments. See Supplementary Figure 16 for additional cell lines. (c) Image of a representative well corresponding to the counts of 3D
spheres in panel b. These images illustrate that both the number and size of the spheres are increased in MCF7 and HCC1937 cells over-
expressing HDAC7-GFP as compared to an EV-expressing control. (d) HDAC7 overexpression increases TIC frequency in MDA-MB-231
xenografts expressing HDAC7-CMV as compared to EV-control. TIC frequency calculated by limiting dilution analysis using http://bioinf.wehi.
edu.au/software/elda/. TIC frequency of control cells (1.14 × 10− 5) and HDAC7 over-expressing cells (H7-CMV) (5.56 × 10− 4)(Po0.03).
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Figure 19), alters Histone 3 (H3) and H3K27 acetylation of stem
cell transcription factor genes and reduces expression of several
stem cell factors such as myc (Supplementary Figures 20 and 21).
Lastly, we found that treatment of a primary ovarian cell line
(OCI-P5x), established from a human high-grade serous ovarian
carcinoma, inhibited mouse xenograft tumour formation in vivo
(Figures 8a–c), and reduced the tumour sphere formation capacity
of the explanted cells from these xenograft tumours. (Figure 8d).
DISCUSSION
In summary, our results show that the paired isogenic BPLER (CSC)
and HMLER (nsTC) cell line pairs can provide a suitable model
system to uncover epigenetic differences between CSC and nsTC.
From a mechanistic perspective, our results suggest that HDAC1 and
HDAC7 may be important for maintaining both normal stem cells
and the CSC phenotype. Interestingly, HDAC1 and HDAC7 have
been implicated in the regulation of normal pluripotency-associated
Figure 7. Isoform-speciﬁc HDACis that inhibit HDAC1 and HDAC7 can be used to selectively target CSCs. (a) The HDAC class I speciﬁc
drugs that also downregulate HDAC7 (MS275 and MGCD) signiﬁcantly inhibit BPLER proliferation (blue bar), with minimal effect on
HMLERs (red bar). The class II speciﬁc HDACi MC1568 and MC1575 also preferentially inhibit BPLER proliferation compared to matched
HMLER lines. In contrast, the HDACi that do not target HDAC1 or HDAC7 (Droxinostat and Apicidin) preferentially inhibit HMLER. The cells
were treated with MS275 (1 μM), MGCD0103 (1 μM), MC1568 (1 μM), MC1575 (1 μM), Apicidin (0.1 μM) and Droxinostat (5 μM). Similar
results were observed with two additional matched BPLER/HMLER pairs, in at least three independent experiments. The viable cells were
assessed with trypan blue staining and counted after four days of treatment. Inhibition in proliferation is represented as a percentage of
vehicle treated control (white bar). The error bars represent the standard deviation of the mean of triplicate samples (Po0.005).
(b) Isoform-speciﬁc HDACis that target HDAC1 and/or HDAC7 (MS-275 and MGCD0103) preferentially inhibit 3D sphere formation (black
bars) compared to 2D proliferation (grey bars). The breast cancer (BPLER, SUM159, MCF7, ZR751) and ovarian cancer (SKOV3) cell lines
were pre-treated for 24 h with MS-275 (1 μM), MGCD0103 (1 μM) or MC1568 (1 μM). The next day, 2D and 3D cultures were established in
drug-free medium. In contrast, pre-treatment with Droxinostat (5 μM) has minimal effects on 2D or 3D cell proliferation. The number of
viable cells for 2D growth was determined by trypan blue staining. The number of 3D spheres was determined by INT staining. Inhibition
in proliferation is represented as a percentage of vehicle treated control (white bar). The error bars represent the standard deviation of the
mean of triplicate samples (*Po0.05) (**Po0.01). (c) The level of HDAC7 protein expression is signiﬁcantly downregulated by short-term
(24 h) treatment with MS-275 or MGCD0103 at 1 μM (low) or 2 μM (high) doses, but not with MC1568 or Droxinostat at 1 μM (low) or 5 μM
(high) doses in SUM159 cells. Similar results are observed with BPLER, MCF7 and MDA-MB-231 cells (data not shown). Western blots of
whole-cell lysates. β-Actin (*) was used as a loading control. (d) MS-275 pretreatment preferentially inhibits 3D sphere formation (black
bars) compared to 2D proliferation (grey bars) in a panel of primary human ovarian cancer cell lines, including; OCI-C5x (clear cell), OCI-
P7a (papillary serous), OCI-P9a1 (papillary serous) and OCI-P5x (papillary serous). The lines were pre-treated for 24 h with 1 μM MS-275, and
plated into 2D and 3D cultures the following day in drug-free medium. The number of viable cells for 2D growth was determined by
trypan blue staining. The number of 3D spheres was determined by INT staining. Inhibition in proliferation is represented as a percentage
of vehicle treated control (white bar). The error bars represent the standard deviation of the mean of triplicate samples (*Po0.05)
(**Po0.01).
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genes4–8,46 and colony formation in normal embryonic stem cells.9,10
In malignant cells the class IIA HDACs are upregulated in breast and
colon cancers compared to other cancers, highly expressed and
associated with poor prognosis in astrocytoma, medulloblastoma
and in childhood acute lymphoblastic leukemia.47–49 HDAC1/7 are
shown to be repressed by the CSC-suppressor MiR-34a,50 which
correlate with prognosis in gliomas and osteosarcomas.51,52
In addition, it was found that Vorinostat downregulates HDAC7 in
bladder and prostate carcinomas.53
The class I HDACs are upregulated in gastric, colorectal,
esophageal, prostate and pancreatic cancer, high HDAC1 expres-
sion is associated with poor prognosis in colorectal cancer,
pancreatic cancer, hepatocellular carcinoma, and lung cancer.54–56
So far, the limited clinical studies have been completed with
MS275 and MGCD0103 predominantly in leukemia and lymphoma
patients.57 However, as the potential CSC-speciﬁc actions of these
drugs were previously unknown, CSC biomarkers were not used in
patient selection or for measuring patient response. As it appears
that the regulation of HDAC1 and HDAC7 levels is predominantly
occurring at the protein level, it would be feasible to use
immunohistochemistry to stratify patients based on HDAC
expression levels for future clinical trials. Furthermore, our results
indicate that in addition to inhibiting HDAC1, MS275 and
MGCD0103 signiﬁcantly downregulate HDAC7 protein levels.
Thus, it might be possible to take advantage of this observation
in monitoring patient response by comparing tumour biopsies
before and after treatment. The signiﬁcant reduction of HDAC7 in
post-treatment biopsies might retrospectively distinguish patients
in whom effective doses were achieved. A similar strategy might
be used to individualize optimum dosing for each patient
prospectively.
In standard trial design with cytostatic and cytotoxic drugs, the
reduction in tumour size has been one of the main metrics for
monitoring patient response. However, as suggested previously,
CSC targeting drugs may not cause a rapid reduction in tumour
size.58 This is because CSCs are thought to comprise a small
portion of the tumour bulk and the remaining nsTC can proliferate
for some time even when CSCs are completely eliminated. Hence,
the effects of CSC targeting drugs may take a long time to result in
a clinically measurable reduction in tumour size. The lag in clinical
response will depend on how many population doublings nsTC
can go through without being replenished by CSCs, which may be
patient and tumour type dependent. These considerations make
the use of biomarkers such as HDAC1 and HDAC7 for patient
selection and monitoring response particularly compelling as a
supplement to tumour size measurements.
Our results also indicate that these drugs should be tested more
extensively in solid tumours, perhaps in combination with
conventional chemotherapeutics to target the nsTC comprising
the tumour bulk. This strategy may address some of the
considerations regarding the lag time in tumour response with
CSC-targeting drugs outlined above. Furthermore, it is thought
that CSCs might be particularly relevant in recurrence and
metastasis.58 Hence, a reduction in long-term recurrence might
be an important metric, in addition to tumour size, to assess the
role of CSC targeting drugs. To our knowledge the CSC-speciﬁc
strategies outlined above were not used for patient selection or
assessing response in previous studies. This is expected because
the CSC-speciﬁc actions of MS275 and MGCD0103 we describe
Figure 8. MS275 inhibits xenograft tumour growth. The OCI-P5X ovarian cancer cell line that express luciferase was treated either with vehicle
(Ctrl) or MS275 at 0.5 μM for 24 h and injected into the right and left ﬂanks of nu/nu Balb/C mice at serial dilutions (106, 105, 104 and 103
cells/site). (a) The tumour growth was monitored with IVIS imaging once a week by intraperitoneal injection of 150 mg/kg D-luciferin 10 min
before scanning. The representative image shows tumour speciﬁc bioluminescence signal in mice at week 6 after OCI-P5X cell injection.
The same scale bar was used between ctrl and MS275 groups at each dilution for comparison. (b) Quantiﬁcation of bioluminescence
intensities in MS275 and control (vehicle) groups 6 weeks after injection. Black dots: Ctrl group. Black circles: MS275. Black line in the middle
of the cluster represents the average signal in each group. (c) The number of gross tumours that formed at each injection site in MS275 and
control (vehicle) groups; 10 sites of injection (5 mice per group, 2 sites/mouse). (d) The number of tumours spheres that are formed by
OCI-P5x explants that were treated with MS275 and control (vehicle). White bar gross tumours that formed at each injection site in MS275
(black bar) and control (white bar). The images show representative wells photographed with regular and ﬂuorescent microscopy
(scale bar= 2000 μm).
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here were previously not fully recognized. Hence, the response in
ongoing and previous studies to HDAC inhibitors should be
viewed with caution; it is possible that better results might be
achieved with careful attention to CSC-associated activities of this
class of drugs. We hope that this report will stimulate efforts for
more innovative clinical trials and development of more selective
HDAC1 and HDAC7 inhibitors that may be even more effective
than those currently available.
MATERIALS AND METHODS
Cell culture
The BPE, BPLER and OCI cells and their culture media BMI-P, BMI-T and
OCMI are available from the Live Tumor Culture Core (LTCC) LTCC@med.
miami.edu, at Sylvester Comprehensive Cancer Center (SCCC), Miller
School of Medicine, University of Miami http://sylvester.org/shared-
resources/Live-Tumor-Culture-Core. The BPE and BPLER cells were cultured
in the BMI-P and BMI-T medium, respectively. The primary ovarian cancer
cells (OCI) were cultured in OCMI medium as previously described,45 while
the primary breast cells (BCI) were cultured in BCMI (unpublished). The
HMLER cells are cultured in MEGM medium (Lonza, Allendale, NJ, USA) as
previously described.23 The standard cancer cell lines were cultured in
ATCC recommended media, at 37 °C and 5 % CO2 on standard plates
(Falcon, New York, NY, USA). All standard cancer cell lines were recently
short tandem repeat proﬁled and tested for mycoplasma contamination
prior to experimentation. The BPE, BPLER, OCI and BCI cells are cultured on
Primaria plates (BD Biosciences, San Jose, CA, USA) as previously
described.23,45
Serial dilution in vivo (BPLER/HMLER)
Single-cell suspensions were prepared in a WIT:Matrigel (1:1) mixture and
injected in 25 μl (orthotopic) or 100 μl (subcutaneous) volumes. Female
athymic nude mice (Balb/c nu/nu, Taconic) were γ-irradiated (400 rad) 12 h
prior to subcutaneous injections. Sample size was determined by degree of
dilution as follows: nine mice/experimental group for 105 and 104 dilution
conditions, 12 mice/experimental set for 103, 102 and 101 dilution
conditions. Animals were randomly assigned to each treatment group.
Injections of tumorigenic cells into mammary fat pads were performed in
8-week-old female Nod/Scid mice that were anesthetized with intraper-
itoneal Avertin. Investigators were not blinded in the animal studies. All
animal studies were approved and performed in accordance with relevant
institutional IACUC committee guidelines.
Mammosphere formation
All mammospheres assays were carried out in BMI-T medium supplemen-
ted with 2 % B27 (Invitrogen, Carlsbad, CA, USA), 20 ng/ml EGF, 20 ng/ml
bFGF (BD Biosciences), 4 μg/ml heparin (Sigma, St Louis, MO, USA) and
0.5% methyl cellulose. Six-well culture plates are coated with poly hema
(20 mg/ml), and 20 000 cells are plated in 4 ml per well. After 2 weeks, the
colonies are stained with 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-phenyl-2H-
tetrazolium chloride (INT), and counted on a Gelcount instrument (Oxford
Optronix, Abingdon, UK). All experiments were carried out with triplicates
and repeated a minimum of three times. The error bars represent the
standard error of the mean of the three replicates.
Flow cytometry and cell sorting
Cells were harvested from sub-conﬂuent culture plates and cell pellets
were washed, resuspended in HBSS buffer containing 0.2 % BSA, and
stained with ﬂuorophore-conjugated monoclonal antibodies per manu-
facturer’s instruction. Antibodies used for cell sorting or analysis included:
anti-CD44, APC conjugated (BD Pharmingen, San Jose, CA, USA; #559942);
anti-CD44, FITC conjugated (Abcam, Cambridge, UK; #ab19622); CD133/1,
PE conjugated (Miltenyi Biotech, Bergisch Gladbach, Germany; #130-080-
801); CD166, PE conjugated (BD Pharmingen, #559263); CD326, FITC
conjugated (AbD # MCA1870F); and CD326, PerCP-Cy5.5 conjugated (BD
Pharmingen, #347199). Flow cytometry analysis was performed using an
Accuri C6 cytometer (Accuri cytometers Inc., San Jose, CA, USA). Sorted
cells were collected in heat-inactivated fetal serum or HBSS buffer
containing 2 % BSA. Purity of sorted cells was between 90 and 95 %.
Western blotting
Whole-cell lysates, harvested with RIPA buffer containing protease and
phosphatase inhibitors, were run on 4–15 % SDS-PAGE gradient gels
(Biorad, Hercules, CA, USA). Blots were blocked in 5 % milk, then probed
with antibodies; CD326 (Cell Signaling, Danvers, MA, USA; #2929 S), CD166
(Abcam#ab49496), CD44(2c5) (R&D#BBA10), BMI-1 (Cell Signaling#2830 S),
HDAC1 (Cell Signaling#5356), HDAC2 (Cell Signaling#5113), HDAC3 (Cell
Signaling#3949), HDAC4 (Cell Signaling#7628), HDAC5 (Cell Signal-
ing#2082), HDAC6 (Novus, Littleton, CO, USA; #91805), HDAC7 (Abca-
m#ab12174), HDAC8 (Novus#91807), HDAC9 (Abcam#ab18970), HDAC10
(Novus#91801). Blots were developed using SuperSignal West Pico or Femto
ECL (ThermoScientiﬁc, Waltham, MA, USA). All experiments were repeated a
minimum of three times.
Inhibition of 2D cell proliferation with continuous drug treatment
To assess the effect of long-term drug treatment on 2D proliferation of
BPLER and HMLER cells, they were plated at a density of 250 000 cells/well
in six-well Primaria plates. After 24 h, drug-containing media was added to
each well. Cells were treated continuously for 4 days, at which point cell
counts and viability (based on Trypan blue exclusion) were quantiﬁed
using a Nexelcom Cellometer, and assessed as a percentage of control
cells. All treatments were done in triplicates, and repeated a minimum of
three times.
Inhibition of 2D/3D cell proliferation with drug pretreatment
To assess effect of short-term drug pretreatment on 2D/3D growth, cells
are plated in six-well plates and allowed to recover for 24 h. At this point,
drug-containing media was added to each well. After 24 h of treatment,
cells were then were plated for mammospheres or 2D proliferation assays.
2D proliferation was determined after 3 days by viable cell counts, and
assessed as a percentage of the dimethyl sulfoxide control. All treatments
were carried out in triplicate, and repeated a minimum of three times. The
error bars represent the standard error of the mean of the three replicates.
The small molecule drugs that are used to treat the cells for various
experiments are: TSA (Selleck, Boston, MA, USA) Doxirubicin (Selleck),
Paclitaxel (Selleck), 5-Fluorouracil (Sigma), SAHA (Selleck), GSK126 (Cayman
Chem), MS275 (Selleck), MGCD0103 (Selleck), MC1568 (Selleck), MC1575
(Gift of Dr. Antonello Mai), Apicidin (Sigma), Droxinostat (Selleck). All drugs
are prepared in dimethyl sulfoxide, which was used as vehicle control in
each assay.
mRNA expression analysis
mRNA analysis as previously described23 using Affymatrix human 133 2.0.
Apoptosis
The cells lines were treated with drugs for 24 h at the following doses: 5-FU
(50 μM), Taxol (50 nM), Doxirubicin (5 μM). Cells were then assayed for
apoptosis with Annexin V-PE apoptosis kit (Abcam#ab14155) as per the
manufacturer’s protocol. All experiments were carried out in triplicates,
and repeated a minimum of three times.
Immunoﬂuorescence
The cells were plated on to eight-well chamber slides, ﬁxed with 4 %
paraformaldehyde for 15 min, washed three times with PBS/100 mM
Glycine, and then permeabilized for 15 min with 0.5 % Tween-20. Slides
were then blocked for 1 h in 10 % Goat serum/0.1 % BSA/PBS, incubated
for 1.5 h with primary antibody, followed by 45 min incubation with
ﬂuorophore-conjugated secondary antibody. Slides were mounted with
Fluoro-Gel II, with DAPI (EM Sciences, Hatﬁeld, PA, USA) for nuclear
staining. Cells were imaged on an Evos ﬂuorescence microscope (AMG &
Life Tech, Millcreek, WA, USA). Antibodies: HDAC7 (Abcam#ab12174), CD44
(R&D#BBA10), CD166 (AbD Serotech, Raleigh, NC, USA; #MCA1926T). All
experiments were repeated a minimum of three times.
HDAC activity assay
The cells were harvested and sorted by ﬂow cytometry as described above.
After three washes with cold HBSS buffer cells were lysed in cold lysis
buffer and centrifuged at 4 °C. The protein concentration of the cell lysates
were quantiﬁed by Coomassie Plus Reagent (Thermoscientiﬁc #1856210).
HDAC activity assay (Cayman Chemical Co., Ann Artbor, MI, USA;
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#10011563) was performed according to the manufacture’s protocol. The
data are presented as ﬂuorescence units. All experiments were carried out
in triplicates in each of at least three independent experiments.
shRNA knockdown of HDAC1 and HDAC7
The cell lines were transduced with GIPZ lentiviral shRNAmir constructs
purchased from Open Biosystems (Lafayette, CO, USA)/ThermoScientiﬁc
(Catalog # V3LHS_351665, V2LHS_96400, V2LHS_96401). HDAC1 cell lines
were transduced with MISSION shRNA purchased from Sigma (Catalog#
TRCN0000195467, TRCN0000195672, TRCN0000195103, TRCN0000195672).
The cell lines that stably express the shRNAs were selected for puromycin
resistance. All experiments were performed in triplicate, and repeated a
minimum of three times.
siRNA knockdown of HDAC7
HDAC7 siRNA (Sigma#EHU078781) was transfected into cell lines with
Mission Transfection Reagent (Sigma#S1452) as per manufacturer’s
protocol. Transfected cells plated in triplicate in 2D/3D assays and lysates
harvested at 72 h post-transfection. All experiments were repeated a
minimum of three times.
Over-expression of HDAC1 and HDAC7
HDAC1-Flag (provided by Eric Verdin through Addgene, Cambridge, MA,
USA; plasmid#13820) and HDAC7 (purchased from Origene, Rockville, MD,
USA; cat. #RC215233) were cloned into pENTR vectors. These constructs
were recombined into pLenti CMV DEST lentiviral vectors (provided by Eric
Campeau through Addgene). Lentivirus was packaged in 293T cells using
the manufacturer’s recommended protocols. Stable lines were selected
with G418 (HDAC7) or Blast (HDAC1). All experiments were carried out in
triplicate, and repeated a minimum of three times.
Serial dilution in vivo (knockdown/overexpression)
MDA-MB-231-luciferase cells were transduced with lentivirus and selected
for stable expression of HDAC7-CMV, empty vector control (EV), HDAC1
shRNA (Construct #1 and Contruct #2), or a scramble shRNA control.
HDAC7-overexpression, or HDAC1 knockdown was conﬁrmed by western
blot. Serial dilutions of MDA-MB-231-luciferase cells were injected
(1 000 000, 100 000, 10 000, 1000, or 100 cells suspended in 100 μl of
HBSS:Matrigel) into the mammary fat pad of 5-week-old, female, Balb/C
nude mice (Charles River, Wilmington, MA, USA) at the rate of three
injections per mouse. The mice were randomly assigned to each
treatment group. Tumours were followed by weekly IVIS analysis
beginning at 5 weeks. The mice that died post-injection and prior to
IVIS imaging were eliminated from analysis. The tumours were also
visually scored (+/− ) and each tumour was measured at its maximum
diameter. Tumours from 1 000 000 and 100 000 dilution groups were
excised at 1 cm diameter and animals were examined for metastasis. All
others tumours were excised per Animal Care and Use Committee or at
100 days if no tumour arose. Tumour luciferase signals were analysed by
Living Image In Vivo imaging software (Perkin Elmer, Waltham, MA, USA)
and plotted using GraphPad Prism 5.0. Investigators were not blinded in
the animal studies. All animal studies were approved and performed in
accordance with relevant institutional IACUC committee guidelines.
Serial dilution in vivo (MS-275 treatment)
The primary ovarian cancer cell line OCI-P5X that expresses luciferase-
GFP (OCI-P5X Fluc-IRES-GFP) was plated on T-75 ﬂasks and treated
with either 0.5 μM MS275 or vehicle control for 24 h. After trypsinization,
serial dilutions were injected (1 000 000, 100 000, 10 000, or 1000 cells
suspended in 100 μl of 1:1 HBSS: Matrigel) into the left and right
ﬂanks of 5-week-old Balb/C nude mice (Charles River). Animals were
randomly assigned to each treatment group. Tumours were followed
by weekly IVIS analysis beginning at 1 week. Tumour luciferase signals
were analysed by Living Image In Vivo imaging software (Perkin
Elmer) and plotted using GraphPad Prism 5.0. Investigators were not
blinded in the animal studies. All animal studies were approved and
performed in accordance with relevant institutional IACUC committee
guidelines.
Statistical analysis
Cell proliferation, sphere formation and HDAC activities were compared by
two-tailed Student’s t-test, using GraphPad Prism 5.0, GraphPad Software
with Po0.05 considered signiﬁcant. Limiting dilution analysis was done
with http://bioinf.wehi.edu.au/software/elda/index.html.59
CONFLICT OF INTEREST
Tan A. Ince discloses pending patent intellectual proprietary interest as the inventor
of BMI and OCMI media.
ACKNOWLEDGEMENTS
This work was funded by grants from: (1) Sylvester Comprehensive Cancer Center, Miller
School of Medicine, University of Miami (TAI); (2) Breast Cancer Research Foundation,
New York, NY (TAI); (3) Women’s Cancer Association (TAI); (4) DoD-CDMRP Ovarian Cancer
Research Program (W81XWH-14-1-0160) Resource Development Grant OC130649 (TAI),
and (5) National Cancer Institute, Roadmap Epigenomics project (R01-CA146445-01) to TAI,
TIL and RAY. We thank Jayanta Debnath for his help with 3D morphogenesis assays, Dr
Antonello Mai for providing MC1575, Chuck Harrell for help with mRNA expression array
analysis, P.L. Guevara for help with FACs analysis, Noriyuki Kasahara and Sara Collins for
transduction of OCI-P5x cell line with luciferase and F. Reinhardt for technical assistance.
AUTHOR CONTRIBUTIONS
Conception, design and study supervision (Tan A. Ince, Abigail E. Witt), development
of methodology and cell culture medium (Tan A. Ince), acquisition of data (Abigail E.
Witt, Chung-Wei Lee, Tong Ihn Lee, Diana J. Azzam, Fabio Petrocca, James Grosso,
Evan B. Cohick, Bin Wang, Corrado Caslini, Michelle Jones and Adrienne B. Gropper),
bioinformatic, computational, statistical analysis and interpretation (Tan A. Ince,
Richard A Young, Fabio Petrocca, Andrea L. Richardson, Ramin Shiekhattar), writing,
review and revision of the manuscript (Tan A. Ince and Abigail E. Witt).
REFERENCES
1 Ablett MP, Singh JK, Clarke RB. Stem cells in breast tumours: are they ready for the
clinic? Eur J Cancer [Research Support, Non-US Gov’t Review] 2012; 48: 2104–2116.
2 Vincent A, Van Seuningen I. On the epigenetic origin of cancer stem cells. Bio-
chimica et biophysica acta 2012; 1826: 83–88.
3 Seto E, Yoshida M. Erasers of histone acetylation: the histone deacetylase
enzymes. Cold Spring Harb Perspect Biol [Review] 2014; 6: a018713.
4 Kidder BL, Palmer S. HDAC1 regulates pluripotency and lineage speciﬁc tran-
scriptional networks in embryonic and trophoblast stem cells. Nucleic Acids Res
2012; 40: 2925–2939.
5 Liang J, Wan M, Zhang Y, Gu P, Xin H, Jung SY et al. Nanog and Oct4 associate
with unique transcriptional repression complexes in embryonic stem cells. Nat
Cell Biol 2008; 10: 731–739.
6 Dovey OM, Foster CT, Cowley SM. Histone deacetylase 1 (HDAC1), but not HDAC2,
controls embryonic stem cell differentiation. Proc Natl Acad Sci USA 2010; 107:
8242–8247.
7 McCool KW, Xu X, Singer DB, Murdoch FE, Fritsch MK. The role of histone acet-
ylation in regulating early gene expression patterns during early embryonic stem
cell differentiation. J Biol Chem 2007; 282: 6696–6706.
8 Karantzali E, Schulz H, Hummel O, Hubner N, Hatzopoulos A, Kretsovali A. Histone
deacetylase inhibition accelerates the early events of stem cell differentiation:
transcriptomic and epigenetic analysis. Genome Biol 2008; 9: R65.
9 Zhu C, Chen Q, Xie Z, Ai J, Tong L, Ding J et al. The role of histone deacetylase 7
(HDAC7) in cancer cell proliferation: regulation on c-Myc. J Mol Med (Berl) 2011;
89: 279–289.
10 You JS, Kang JK, Seo DW, Park JH, Park JW, Lee JC et al. Depletion of embryonic
stem cell signature by histone deacetylase inhibitor in NCCIT cells: involvement of
Nanog suppression. Cancer Res 2009; 69: 5716–5725.
11 Jiao J, Hindoyan A, Wang S, Tran LM, Goldstein AS, Lawson D et al. Identiﬁcation
of CD166 as a surface marker for enriching prostate stem/progenitor and cancer
initiating cells. PloS One [Research Support, N.I.H., Extramural Research Support,
Non-US Gov’t Research Support, US Gov’t, Non-P.H.S.] 2012; 7: e42564.
12 Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW et al. Phenotypic character-
ization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 2007; 104:
10158–10163.
13 Rowehl RA, Burke S, Bialkowska AB, Pettet DW 3rd, Rowehl L, Li E et al. Estab-
lishment of highly tumorigenic human colorectal cancer cell line (CR4) with
properties of putative cancer stem cells. PloS One [Research Support, Non-US Gov’t]
2014; 9: e99091.
Identiﬁcation of cancer stem cell-speciﬁc function for HDACs
AE Witt et al
1718
Oncogene (2017) 1707 – 1720
14 Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-like cells
that self-renew, give rise to phenotypically diverse progeny and survive che-
motherapy. Breast Cancer Res: BCR. [Research Support, N.I.H., Extramural Research
Support, Non-US Gov’t] 2008; 10: R25.
15 Stuelten CH, Mertins SD, Busch JI, Gowens M, Scudiero DA, Burkett MW et al.
Complex display of putative tumor stem cell markers in the NCI60 tumor cell
line panel. Stem Cells [Research Support, N.I.H., Extramural Research Support, N.I.H.,
Intramural] 2010; 28: 649–660.
16 Kok M, Koornstra RH, Margarido TC, Fles R, Armstrong NJ, Linn SC et al.
Mammosphere-derived gene set predicts outcome in patients with ER-positive
breast cancer. J Pathol [Research Support, Non-US Gov’t] 2009; 218: 316–326.
17 Azzam DJ, Zhao D, Sun J, Minn AJ, Ranganathan P, Drews-Elger K et al. Triple
negative breast cancer initiating cell subsets differ in functional and molecular
characteristics and in gamma-secretase inhibitor drug responses. EMBO Mol Med
[Research Support, N.I.H., Extramural Research Support, Non-US Gov’t Research
Support, US Gov’t, Non-P.H.S.] 2013; 5: 1502–1522.
18 Civenni G, Walter A, Kobert N, Mihic-Probst D, Zipser M, Belloni B et al. Human
CD271-positive melanoma stem cells associated with metastasis establish tumor
heterogeneity and long-term growth. Cancer Res [Research Support, Non-US Gov’t]
2011; 71: 3098–3109.
19 Munz M, Baeuerle PA, Gires O. The emerging role of EpCAM in cancer and stem
cell signaling. Cancer Res [Research Support, Non-US Gov’t Review] 2009; 69:
5627–5629.
20 Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY et al. EpCAM-positive
hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor
cell features. Gastroenterology [Research Support, N.I.H., Extramural Research
Support, Non-US Gov’t Research Support, US Gov’t, Non-P.H.S.] 2009; 136:
1012–1024.
21 Williams K, Motiani K, Giridhar PV, Kasper S. CD44 integrates signaling in normal
stem cell, cancer stem cell and (pre)metastatic niches. Exp Biol Med (Maywood)
[Research Support, N.I.H., Extramural Research Support, Non-US Gov’t Review] 2013;
238: 324–338.
22 Belsky DW, Mofﬁtt TE, Baker TB, Biddle AK, Evans JP, Harrington H et al. Polygenic
risk and the developmental progression to heavy, persistent smoking and nico-
tine dependence: evidence from a 4-decade longitudinal study. JAMA Psychiatry
[Research Support, N.I.H., Extramural Research Support, Non-US Gov’t Research
Support, US Gov’t, P.H.S.] 2013; 70: 534–542.
23 Ince TA, Richardson AL, Bell GW, Saitoh M, Godar S, Karnoub AE et al. Transfor-
mation of different human breast epithelial cell types leads to distinct tumor
phenotypes. Cancer Cell 2007; 12: 160–170.
24 Sauder CA, Koziel JE, Choi M, Fox MJ, Grimes BR, Badve S et al.
Phenotypic plasticity in normal breast derived epithelial cells. BMC Cell Biol 2014;
15: 20.
25 Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T et al. Identiﬁcation of
human brain tumour initiating cells. Nature [Research Support, Non-US Gov’t] 2004;
432: 396–401.
26 Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D et al.
Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/
progenitor cell properties. Cancer Res [Research Support, Non-US Gov’t] 2005; 65:
5506–5511.
27 Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C et al.
Identiﬁcation and expansion of human colon-cancer-initiating cells. Nature
[Research Support, Non-US Gov’t] 2007; 445: 111–115.
28 Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A et al. Identiﬁcation and
expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ
[Research Support, Non-US Gov’t] 2008; 15: 504–514.
29 Han ME, Jeon TY, Hwang SH, Lee YS, Kim HJ, Shim HE et al. Cancer spheres from
gastric cancer patients provide an ideal model system for cancer stem cell
research. Cell Mol Life Sci: CMLS. [Research Support, Non-US Gov’t] 2011; 68:
3589–3605.
30 Merritt MA, Bentink S, Schwede M, Iwanicki MP, Quackenbush J, Woo T et al. Gene
expression signature of normal cell-of-origin predicts ovarian tumor outcomes.
PLoS One 2013; 8: e80314.
31 Petrocca F, Altschuler G, Tan SM, Mendillo ML, Yan H, Jerry DJ et al. A genome-
wide siRNA screen identiﬁes proteasome addiction as a vulnerability of basal-like
triple-negative breast cancer cells. Cancer Cell 2013; 24: 182–196.
32 Leth-Larsen R, Terp MG, Christensen AG, Elias D, Kuhlwein T, Jensen ON et al.
Functional heterogeneity within the CD44 high human breast cancer stem cell-
like compartment reveals a gene signature predictive of distant metastasis. Mol
Med [Research Support, Non-US Gov’t] 2012; 18: 1109–1121.
33 Pasto A, Bellio C, Pilotto G, Ciminale V, Silic-Benussi M, Guzzo G et al. Cancer stem
cells from epithelial ovarian cancer patients privilege oxidative phosphorylation,
and resist glucose deprivation. Oncotarget [Research Support, Non-US Gov’t] 2014;
5: 4305–4319.
34 Kasler HG, Young BD, Mottet D, Lim HW, Collins AM, Olson EN et al. Histone
deacetylase 7 regulates cell survival and TCR signaling in CD4/CD8 double-
positive thymocytes. J Immunol [Research Support, N.I.H., Extramural] 2011; 186:
4782–4793.
35 Schuettengruber B, Simboeck E, Khier H, Seiser C. Autoregulation of mouse his-
tone deacetylase 1 expression. Mol Cell Biol [Research Support, Non-US Gov’t] 2003;
23: 6993–7004.
36 Chikamatsu K, Ishii H, Murata T, Sakakura K, Shino M, Toyoda M et al. Alteration of
cancer stem cell-like phenotype by histone deacetylase inhibitors in squamous
cell carcinoma of the head and neck. Cancer Sci [Research Support, Non-US Gov’t]
2013; 104: 1468–1475.
37 Salvador MA, Wicinski J, Cabaud O, Toiron Y, Finetti P, Josselin E et al. The histone
deacetylase inhibitor abexinostat induces cancer stem cells differentiation in
breast cancer with low Xist expression. Clin Cancer Res: An Ofﬁcial Journal of the
American Association for Cancer Research [Research Support, Non-US Gov’t] 2013;
19: 6520–6531.
38 Debeb BG, Lacerda L, Xu W, Larson R, Solley T, Atkinson R et al. Histone deace-
tylase inhibitors stimulate dedifferentiation of human breast cancer cells through
WNT/beta-catenin signaling. Stem Cells [Research Support, N.I.H., Extramural
Research Support, Non-US Gov’t] 2012; 30: 2366–2377.
39 Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM. The
histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differ-
entiation of human breast cancer cells. Cancer Res [Research Support, US Gov’t, P.H.
S.] 2001; 61: 8492–8497.
40 Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Hardwick JS et al. Phase II
trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer
treatment group study. J Clin Oncol: Ofﬁcial Journal of the American Society of
Clinical Oncology [Clinical Trial, Phase II Research Support, N.I.H., Extramural
Research Support, Non-US Gov’t] 2009; 27: 2052–2058.
41 Beckers T, Burkhardt C, Wieland H, Gimmnich P, Ciossek T, Maier T et al. Distinct
pharmacological properties of second generation HDAC inhibitors with the
benzamide or hydroxamate head group. Int J Cancer [Journal international du
cancer] 2007; 121: 1138–1148.
42 Boissinot M, Inman M, Hempshall A, James SR, Gill JH, Selby P et al. Induction of
differentiation and apoptosis in leukaemic cell lines by the novel benzamide
family histone deacetylase 2 and 3 inhibitor MI-192. Leukemia Res [Research
Support, Non-US Gov’t] 2012; 36: 1304–1310.
43 Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N et al. Determination
of the class and isoform selectivity of small-molecule histone deacetylase inhi-
bitors. Biochem J 2008; 409: 581–589.
44 Wood TE, Dalili S, Simpson CD, Sukhai MA, Hurren R, Anyiwe K et al.
Selective inhibition of histone deacetylases sensitizes malignant cells to death
receptor ligands. Mol Cancer Ther [Research Support, Non-US Gov’t] 2010; 9:
246–256.
45 Ince TA, Sousa AD, Jones MA, Harrell JC, Agoston ES, Krohn M et al. Character-
ization of twenty-ﬁve ovarian tumour cell lines that phenocopy primary tumours.
Nat Commun 2015; 6: 7419.
46 Zhang L, Jin M, Margariti A, Wang G, Luo Z, Zampetaki A et al. Sp1-dependent
activation of HDAC7 is required for platelet-derived growth factor-BB-induced
smooth muscle cell differentiation from stem cells. J Biol Chem 2010; 285:
38463–38472.
47 Clocchiatti A, Di Giorgio E, Ingrao S, Meyer-Almes FJ, Tripodo C, Brancolini C. Class
IIa HDACs repressive activities on MEF2-depedent transcription are associated
with poor prognosis of ER(+) breast tumors. FASEB Journal: Ofﬁcial publication of
the Federation of American Societies for Experimental Biology [Research Support,
Non-US Gov’t] 2013; 27: 942–954.
48 Milde T, Oehme I, Korshunov A, Kopp-Schneider A, Remke M, Northcott P et al.
HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratiﬁcation and
role in tumor cell growth. Clini Cancer Res: An Ofﬁcial Journal of the American
Association for Cancer Research [Research Support, Non-US Gov’t] 2010; 16:
3240–3252.
49 Van Damme M, Crompot E, Meuleman N, Mineur P, Bron D, Lagneaux L et al.
HDAC isoenzyme expression is deregulated in chronic lymphocytic leukemia
B-cells and has a complex prognostic signiﬁcance. Epigenetics: Ofﬁcial Journal
of the DNA Methylation Society [Research Support, Non-US Gov’t] 2012; 7:
1403–1412.
50 Wu MY, Fu J, Xiao X, Wu J, Wu RC. MiR-34a regulates therapy resistance
by targeting HDAC1 and HDAC7 in breast cancer. Cancer Lett 2014; 354:
311–319.
51 Wang Y, Jia LS, Yuan W, Wu Z, Wang HB, Xu T et al. Low miR-34a and miR-192 are
associated with unfavorable prognosis in patients suffering from osteosarcoma.
Am J Transl Res 2015; 7: 111–119.
52 Gao H, Zhao H, Xiang W. Expression level of human miR-34a correlates with
glioma grade and prognosis. J Neurooncol 2013; 113: 221–228.
Identiﬁcation of cancer stem cell-speciﬁc function for HDACs
AE Witt et al
1719
Oncogene (2017) 1707 – 1720
53 Dokmanovic M, Perez G, Xu W, Ngo L, Clarke C, Parmigiani RB et al. Histone
deacetylase inhibitors selectively suppress expression of HDAC7. Mol Cancer Ther
2007; 6: 2525–2534.
54 Higashijima J, Kurita N, Miyatani T, Yoshikawa K, Morimoto S, Nishioka M et al.
Expression of histone deacetylase 1 and metastasis-associated protein 1 as
prognostic factors in colon cancer. Oncol Rep [Research Support, Non-US Gov’t]
2011; 26: 343–348.
55 Miyake K, Yoshizumi T, Imura S, Sugimoto K, Batmunkh E, Kanemura H et al.
Expression of hypoxia-inducible factor-1alpha, histone deacetylase 1, and
metastasis-associated protein 1 in pancreatic carcinoma: correlation with poor
prognosis with possible regulation. Pancreas 2008; 36: e1–e9.
56 Minamiya Y, Ono T, Saito H, Takahashi N, Ito M, Mitsui M et al. Expression of
histone deacetylase 1 correlates with a poor prognosis in patients with adeno-
carcinoma of the lung. Lung Cancer 2011; 74: 300–304.
57 Garcia-Manero G, Assouline S, Cortes J, Estrov Z, Kantarjian H, Yang H et al. Phase 1
study of the oral isotype speciﬁc histone deacetylase inhibitor MGCD0103 in leukemia.
Blood [Clinical Trial, Phase I Research Support, Non-US Gov’t] 2008; 112: 981–989.
58 Carrasco E, Alvarez PJ, Prados J, Melguizo C, Rama AR, Aranega A et al. Cancer
stem cells and their implication in breast cancer. Eur J Clin Invest [Research Sup-
port, Non-US Gov’t Review] 2014; 44: 678–687.
59 Hu Y, Smyth GK. ELDA: extreme limiting dilution analysis for comparing depleted
and enriched populations in stem cell and other assays. J Immunol Methods
[Comparative Study] 2009; 347: 70–78.
This work is licensed under a Creative Commons Attribution-
NonCommercial-NoDerivs 4.0 International License. The images or
other third party material in this article are included in the article’s Creative Commons
license, unless indicatedotherwise in the credit line; if thematerial is not included under
the Creative Commons license, users will need to obtain permission from the license
holder to reproduce the material. To view a copy of this license, visit http://
creativecommons.org/licenses/by-nc-nd/4.0/
© The Author(s) 2017
Supplementary Information accompanies this paper on the Oncogene website (http://www.nature.com/onc)
Identiﬁcation of cancer stem cell-speciﬁc function for HDACs
AE Witt et al
1720
Oncogene (2017) 1707 – 1720
